Skip to main content
SpringerLink
Log in

Prognosis and Outcomes of ANCA-Associated Vasculitis

  • Chapter
  • First Online:
Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis

Part of the book series: Rare Diseases of the Immune System ((RDIS))

  • 961 Accesses

Abstract

In the modern therapeutic era the outcome of systemic vasculitis has changed from a usually fatal course to a chronic relapsing disorder [1]. During this period, the ANCA vasculitides have been defined and have received the most research attention, especially concerning treatment regimens and the longer term consequences of disease. Achievement of initial disease control, and removal of a direct threat to life or further organ damage, is now considered routine and physicians are concerned with their patients’ longer term health, prevention of further disease flares and comorbidities, minimizing the toxic consequences of treatment, and improving quality of life. From a research perspective, this has meant development of disease state definitions and objective quantification of disease activity and long-term outcome parameters, such as damage and glucocorticoid toxicity [2, 3]. The Birmingham Vasculitis Activity Score (BVAS) and its subsequent modifications are routinely used for activity assessment, while the vasculitis damage index (VDI) has been developed to assess all-cause damage after the vasculitis diagnosis. Disease-specific quality-of-life tools are in development and approaches to economic evaluation are at an early stage [4, 5].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener’s granulomatosis). Br Med J. 1958;2:265–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bacon PA, Moots RJ, Exley A, Luqmani R, Rasmussen N. VITAL (Vasculitis Integrated Assessment Log) assessment of vasculitis. Clin Exp Rheumatol. 1995;13:275–8.

    CAS  PubMed  Google Scholar 

  3. Miloslavsky EM, Naden RP, Bijlsma JW, et al. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017;76(3):543–6.

    Article  PubMed  Google Scholar 

  4. Robson JC, Tomasson G, Milman N, et al. OMERACT endorsement of patient-reported outcome instruments in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol. 2017;44:1529–35.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Robson JC, Dawson J, Cronholm PF, et al. Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure. Patient Relat Outcome Meas. 2018;9:17–34.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Merkel PA, Lo GH, Holbrook JT, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med. 2005;142:620–6.

    Article  PubMed  Google Scholar 

  7. Suppiah R, Judge A, Batra R, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener’s granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken). 2011;63:588–96.

    Article  Google Scholar 

  8. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116:488–98.

    Article  CAS  PubMed  Google Scholar 

  9. Jayne DR, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28(9):2756–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Pagnoux C, Carette S, Khalidi NA, et al. Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol. 2015;33:77–83.

    Google Scholar 

  11. Jayne D, Rasmussen N. Twenty-five years of European Union collaboration in ANCA-associated vasculitis research. Nephrol Dial Transplant. 2015;30:i1–7.

    Article  CAS  PubMed  Google Scholar 

  12. Heijl C, Mohammad AJ, Westman K, Höglund P. Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis. RMD Open. 2017;3:e000435.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Miloslavsky E, Specks U, Merkel P, et al. Clinical outcomes of remission induction therapy for severe ANCA-Associated vasculitis. Arthritis Rheum. 2013;65(9):2441–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Seror R, Pagnoux C, Ruivard M, et al. Treatment strategies and outcome of induction-refractory Wegener’s granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. Ann Rheum Dis. 2010;69:2125–30.

    Article  PubMed  Google Scholar 

  15. Gallagher H, Kwan JT, Jayne DR. Pulmonary renal syndrome: a 4-year, single-center experience. Am J Kidney Dis. 2002;39:42–7.

    Article  PubMed  Google Scholar 

  16. Pagnoux C, Hogan SL, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 2008;58:2908–18.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Walsh M, Flossmann O, Berden A, et al. Risk factors for relapse of ANCA associated vasculitis. Arthritis Rheum. 2012;64(2):542–8.

    Article  CAS  PubMed  Google Scholar 

  18. Göçeroğlu A, Berden AE, Fiocco M, et al. ANCA-associated glomerulonephritis: risk factors for renal relapse. PLoS One. 2016;11:e0165402.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Karras A, Pagnoux C, Haubitz M, et al. European VS. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(10):1662–8.

    Article  CAS  PubMed  Google Scholar 

  20. Walsh M, Merkel PA, Mahr A, Jayne D. The effects of duration of glucocorticoid therapy on relapse rate in anti-neutrophil cytoplasm antibody associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken). 2010;62:1166–73.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790–803.

    Article  CAS  PubMed  Google Scholar 

  22. Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304(21):2381–8.

    Article  CAS  PubMed  Google Scholar 

  23. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771–80.

    Article  PubMed  CAS  Google Scholar 

  24. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369:417–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis Rheum. 2012;64(11):3760–9.

    Article  CAS  PubMed  Google Scholar 

  26. Alberici F, Smith RM, Jones RB, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2015;54(7):1153–60.

    Article  CAS  Google Scholar 

  27. Rasmussen N, Wiik A, Jayne DR. A historical essay on detection of anti-neutrophil cytoplasmic antibodies. Nephrol Dial Transplant. 2015;30:i8–i13.

    CAS  PubMed  Google Scholar 

  28. Morgan MD, Szeto M, Walsh M, et al. Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. Arthritis Res Ther. 2017;19:129.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford). 2006;45:724–9.

    Article  CAS  Google Scholar 

  30. Novack SN, Pearson CM. Cyclophosphamide therapy in Wegener’s granulomatosis. N Engl J Med. 1971;284:938–42.

    Article  CAS  PubMed  Google Scholar 

  31. Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70:488–94.

    Article  PubMed  Google Scholar 

  32. Gayraud M, Guillevin L, le Toumelin P, et al. French VSG. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. 2001;44:666–75.

    Article  CAS  PubMed  Google Scholar 

  33. Bai YH, Li ZY, Chang DY, Chen M, Kallenberg CG, Zhao MH. The BVAS is an independent predictor of cardiovascular events and cardiovascular disease-related mortality in patients with ANCA-associated vasculitis: a study of 504 cases in a single Chinese center. Semin Arthritis Rheum. 2018;47:524–9.

    Article  PubMed  Google Scholar 

  34. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90:19–27.

    Article  Google Scholar 

  35. Mahr A, Katsahian S, Varet H, et al. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis. 2012;72(6):1003–10.

    Article  PubMed  Google Scholar 

  36. Rahmattulla C, de Lind van Wijngaarden RA, Berden AE, et al. Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials. Rheumatology (Oxford). 2015;54(5):899–907.

    Article  CAS  Google Scholar 

  37. Krafcik SS, Covin RB, Lynch JP, Sitrin RG. Wegener’s granulomatosis in the elderly. Chest. 1996;109:430–7.

    Article  CAS  PubMed  Google Scholar 

  38. Little MA, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010;69(6):1036–43.

    Article  PubMed  Google Scholar 

  39. Houben E, Groenland SL, van der Heijden JW, Voskuyl AE, Doodeman HJ, Penne EL. Relation between duration of the prodromal phase and renal damage in ANCA-associated vasculitis. BMC Nephrol. 2017;18:378.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials. 2013;14:73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Hauer HA, Bajema IM, van Houwelingen HC, et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int. 2002;61:80–9.

    Article  PubMed  Google Scholar 

  42. Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21:1628–36.

    Article  PubMed  Google Scholar 

  43. Quintana LF, Perez NS, De Sousa E, et al. ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis. Nephrol Dial Transplant. 2014;29(9):1764–9.

    Article  CAS  PubMed  Google Scholar 

  44. Berden AE, Jones RB, Erasmus DD, et al. Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. J Am Soc Nephrol. 2012;23:313–21.

    Article  CAS  PubMed  Google Scholar 

  45. Vergunst CE, van Gurp E, Hagen EC, et al. An index for renal outcome in ANCA-associated glomerulonephritis. Am J Kidney Dis. 2003;41:532–8.

    Article  PubMed  Google Scholar 

  46. Jayne DR, Marshall PD, Jones SJ, Lockwood CM. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int. 1990;37:965–70.

    Article  CAS  PubMed  Google Scholar 

  47. Alchi B, Griffiths M, Sivalingam M, Jayne D, Farrington K. Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort. Nephrol Dial Transplant. 2015;30(5):814–21.

    Article  CAS  PubMed  Google Scholar 

  48. Bakoush O, Segelmark M, Torffvit O, Ohlsson S, Tencer J. Urine IgM excretion predicts outcome in ANCA-associated renal vasculitis. Nephrol Dial Transplant. 2006;21:1263–9.

    Article  CAS  PubMed  Google Scholar 

  49. Rhee RL, Davis JC, Ding L, et al. The utility of urinalysis in determining the risk of renal relapse in ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2018;13:251–7.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Crnogorac M, Horvatic I, Kacinari P, Ljubanovic DG, Galesic K. Serum C3 complement levels in ANCA associated vasculitis at diagnosis is a predictor of patient and renal outcome. J Nephrol. 2018;31:257–62.

    Article  CAS  PubMed  Google Scholar 

  51. Berden AE, Nolan SL, Morris HL, et al. Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCA-associated vasculitis. J Am Soc Nephrol. 2010;21:2169–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Moiseev S, Novikov P, Jayne D, Mukhin N. End-stage renal disease in ANCA-associated vasculitis. Nephrol Dial Transplant. 2017;32(2):248–53.

    CAS  PubMed  Google Scholar 

  53. Hruskova Z, Stel VS, Jayne D, et al. Characteristics and outcomes of granulomatosis with polyangiitis (Wegener) and microscopic polyangiitis requiring renal replacement therapy: results from the European Renal Association-European dialysis and transplant association registry. Am J Kidney Dis. 2015;66(4):613–20.

    Article  PubMed  Google Scholar 

  54. Little MA, Hassan B, Jacques S, et al. Renal transplantation in systemic vasculitis: when is it safe? Nephrol Dial Transplant. 2009;24:3219–25.

    Article  PubMed  Google Scholar 

  55. Robson J, Doll H, Suppiah R, et al. Damage in the ANCA-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2013;74(1):177–84.

    Article  PubMed  Google Scholar 

  56. Robson J, Doll H, Suppiah R, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2015;74(1):177–84.

    Google Scholar 

  57. Iudici M, Pagnoux C, Quartier P, et al. Childhood- versus adult-onset ANCA-associated vasculitides: A nested, matched case-control study from the French Vasculitis Study Group Registry. Autoimmun Rev. 2018;17:108–14.

    Article  PubMed  Google Scholar 

  58. Mohammad AJ, Mortensen KH, Babar J, et al. Pulmonary Involvement in Antineutrophil Cytoplasmic Antibodies (ANCA)-associated vasculitis: the influence of ANCA subtype. J Rheumatol. 2017;44(10):1458–67.

    Article  PubMed  Google Scholar 

  59. Mohammad AJ, Segelmark M, Smith R, et al. Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol. 2017;44(10):1468–75.

    Article  CAS  PubMed  Google Scholar 

  60. Russell BA, Mohan S, Chahal R, Carette S, Pagnoux C, Canadian VNC. Prognostic significance of cavitary lung nodules in granulomatosis with polyangiitis—a clinical and imaging study of 225 patients. Arthritis Care Res (Hoboken). 2017;70(7):1082–9.

    Article  Google Scholar 

  61. Frankel SK, Jayne D. The pulmonary vasculitides. Clin Chest Med. 2010;31:519–36.

    Article  PubMed  Google Scholar 

  62. Hruskova Z, Casian A, Konopasek P, et al. Long-term outcome of severe alveolar haemorrhage in ANCA-associated vasculitis: a retrospective cohort study. Scand J Rheumatol. 2013;42(3):211–4.

    Article  CAS  PubMed  Google Scholar 

  63. Suppiah R, Hadden RD, Batra R, et al. Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2011;50(12):2214–22.

    Article  Google Scholar 

  64. Arulkumaran N, Periselneris N, Gaskin G, et al. Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. Rheumatology (Oxford). 2011;50:2035–43.

    Article  Google Scholar 

  65. Bartunkova J, Pelclova D, Fenclova Z, et al. Exposure to silica and risk of ANCA-associated vasculitis. Am J Ind Med. 2006;49:569–76.

    Article  CAS  PubMed  Google Scholar 

  66. La-Crette J, Royle J, Lanyon PC, Ferraro A, Butler A, Pearce FA. Long-term outcomes of daily oral vs. pulsed intravenous cyclophosphamide in a non-trial setting in ANCA-associated vasculitis. Clin Rheumatol. 2018;37(4):1085–90.

    Article  PubMed  Google Scholar 

  67. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener’s granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998;9:842–52.

    CAS  PubMed  Google Scholar 

  68. Heijl C, Harper L, Flossmann O, et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis. 2011;70:1415–21.

    Article  CAS  PubMed  Google Scholar 

  69. van Daalen EE, Rizzo R, Kronbichler A, et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(6):1064–9.

    Article  PubMed  CAS  Google Scholar 

  70. Kronbichler A, Jayne DR, Specks U. Con: should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab? Nephrol Dial Transplant. 2015;30(7):1075–81.

    Article  CAS  PubMed  Google Scholar 

  71. Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener’s granulomatosis. Am J Respir Crit Care Med. 1995;151:795–9.

    CAS  PubMed  Google Scholar 

  72. Kronbichler A, Jayne DR, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Investig. 2015;45(3):346–68.

    Article  CAS  Google Scholar 

  73. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996;335:16–20.

    Article  CAS  PubMed  Google Scholar 

  74. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Zeher M, Doria A, Lan J, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus. 2011;20(14):1484–93.

    Article  CAS  PubMed  Google Scholar 

  76. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670–80.

    Article  PubMed  Google Scholar 

  77. Pagnoux C, Quéméneur T, Ninet J, et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol. 2015;67:1117–27.

    Article  CAS  PubMed  Google Scholar 

  78. Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003;41:776–84.

    Article  PubMed  Google Scholar 

  79. Agarwal S, Patrick J, Jones J, Smith R, Coles A, Jayne D. Progressive multifocal leucoencephalopathy with Behçet’s disease: an insight into pathophysiology. Rheumatology (Oxford). 2017;56(4):668–70.

    Google Scholar 

  80. Salmela A, Rasmussen N, Tervaert JW, Jayne DR, Ekstrand A, European VSG. Chronic nasal Staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate. Rheumatology (Oxford). 2017;56(6):965–72.

    Article  CAS  Google Scholar 

  81. Néel A, Espitia-Thibault A, Arrigoni PP, et al. Bronchiectasis is highly prevalent in anti-MPO ANCA-associated vasculitis and is associated with a distinct disease presentation. Semin Arthritis Rheum. 2018;48(1):70–6.

    Article  PubMed  Google Scholar 

  82. Marco H, Smith RM, Jones RB, et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord. 2014;15:178.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  83. Roberts DM, Jones RB, Smith RM, et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun. 2015;57:25–9.

    Google Scholar 

  84. Roberts DM, Jones RB, Smith RM, et al. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. J Autoimmun. 2016;57:75–9.

    Google Scholar 

  85. Cortazar FB, Pendergraft WF, Wenger J, Owens CT, Laliberte K, Niles JL. Effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2017;69:1045–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Kronbichler A, Leierer J, Leierer G, European VS, et al. Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides. Rheumatology (Oxford). 2017;56(5):704–8.

    Google Scholar 

  87. Bautz DJ, Preston GA, Lionaki S, et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol. 2008;19:2421–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Chen M, Jayne DR, Zhao MH. Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat Rev Nephrol. 2017;13(6):359–67.

    Article  CAS  PubMed  Google Scholar 

  89. Houben E, Penne EL, Voskuyl AE, et al. Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies. Rheumatology (Oxford). 2018;57:555–62.

    Article  Google Scholar 

  90. Sherer Y, Pagnoux C, Chironi G, et al. Carotid artery intima-media thickness, heat shock proteins and oxidized LDL autoantibodies in systemic necrotizing vasculitis. Rheumatol Int. 2008;28:1099–103.

    Article  CAS  PubMed  Google Scholar 

  91. Kerekes G, Soltesz P, Der H, et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol. 2009;28:705–10.

    Article  PubMed  Google Scholar 

  92. Walsh M, Mukhtyar C, Mahr A, et al. Health related quality of life in patients with newly diagnosed anti-neutrophil cytoplasm antibody associated vasculitis. Arthritis Care Res (Hoboken). 2011;63(7):1055–61.

    Article  Google Scholar 

  93. Basu N, Jones GT, Fluck N, et al. Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis. Rheumatology (Oxford). 2010;49:1383–90.

    Article  Google Scholar 

  94. Basu N, McClean A, Harper L, et al. The characterisation and determinants of quality of life in ANCA associated vasculitis. Ann Rheum Dis. 2014;73(1):207–11.

    Article  PubMed  Google Scholar 

  95. Faurschou M, Sigaard L, Bjorner JB, Baslund B. Impaired health-related quality of life in patients treated for Wegener’s granulomatosis. J Rheumatol. 2010;37:2081–5.

    Article  PubMed  Google Scholar 

  96. Koutantji M, Harrold E, Lane SE, Pearce S, Watts RA, Scott DG. Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum. 2003;49:826–37.

    Article  PubMed  Google Scholar 

  97. Srouji I, Lund V, Andrews P, Edwards C. Rhinologic symptoms and quality-of-life in patients with Churg-Strauss syndrome vasculitis. Am J Rhinol. 2008;22:406–9.

    Article  PubMed  Google Scholar 

  98. Basu N, McClean A, Harper L, et al. Explaining fatigue in ANCA-associated vasculitis. Rheumatology (Oxford). 2013;52(9):1680–5.

    Article  Google Scholar 

  99. Basu N, Murray AD, Jones GT, Reid DM, Macfarlane GJ, Waiter GD. Neural correlates of fatigue in granulomatosis with polyangiitis: a functional magnetic resonance imaging study. Rheumatology (Oxford). 2014;53:2080–7.

    Article  CAS  Google Scholar 

  100. Basu N, McClean A, Harper L, et al. Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology (Oxford). 2014;53(5):953–6.

    Article  CAS  Google Scholar 

  101. Barra L, Borchin RL, Burroughs C, Vasculitis clinical research consortium and the vasculitis patient-powered research network, et al. Impact of vasculitis on employment and income. Clin Exp Rheumatol. 2018;36(Suppl 111(2)):58–64.

    PubMed  PubMed Central  Google Scholar 

  102. Pugnet G, Pagnoux C, Terrier B, et al. Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life. Clin Exp Rheumatol. 2016;34:S54–9.

    PubMed  Google Scholar 

  103. Hickman RA, Gordon C. Causes and management of infertility in systemic lupus erythematosus. Rheumatology (Oxford). 2011;50:1551–8.

    Article  Google Scholar 

  104. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117:1499–506.

    Article  CAS  PubMed  Google Scholar 

  105. Sangle SR, Lutalo PM, Davies RJ, Khamashta MA, D’Cruz DP. B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases. J Autoimmun. 2013;43:55–9.

    Article  CAS  PubMed  Google Scholar 

  106. Conduit C, Yew S, Jose M, Jayne D, Kirkland G. A case of de novo diagnosis anti-neutrophil cytoplasmic antibody-negative pauci-immune necrotising glomerulonephritis in pregnancy.[letter]. Intern Med J. 2017;47(5):600–1.

    Article  PubMed  Google Scholar 

  107. Hilhorst M, Wilde B, van Paassen P, et al. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol Dial Transplant. 2013;28:373–9.

    Article  CAS  PubMed  Google Scholar 

  108. Miloslavsky EM, Niles JL, Wallace ZS, et al. Reducing glucocorticoid duration in ANCA-associated vasculitis: a pilot trial. Semin Arthritis Rheum. 2018;48(2):288–92.

    Article  CAS  PubMed  Google Scholar 

  109. McAdoo SP, Medjeral-Thomas N, Gopaluni S, et al. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant. 2018;33(5):899.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Furuta S, Chaudhry AN, Hamano Y, et al. Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. J Rheumatol. 2014;41:325–33.

    Article  PubMed  Google Scholar 

  111. Fujimoto S, Watts RA, Kobayashi S, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the UK. Rheumatology (Oxford). 2011;50(10):1916–20.

    Article  Google Scholar 

  112. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7:23–32.

    CAS  PubMed  Google Scholar 

  113. Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-Associated Vasculitis. N Engl J Med. 2012;367:214–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. McKinney EF, Lee JC, Jayne DR, Lyons PA, Smith KG. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature. 2015;523(7562):612–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Cambridge, Cambridge, UK

    David Jayne

Authors
  1. David Jayne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Jayne .

Editor information

Editors and Affiliations

  1. Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Monza e Brianza, Italy

    Renato Alberto Sinico

  2. Department of Medicine, Paris Descartes University Hospital Cochin, Paris, France

    LoĂŻc Guillevin

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Jayne, D. (2020). Prognosis and Outcomes of ANCA-Associated Vasculitis. In: Sinico, R., Guillevin, L. (eds) Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis. Rare Diseases of the Immune System. Springer, Cham. https://doi.org/10.1007/978-3-030-02239-6_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-02239-6_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-02238-9

  • Online ISBN: 978-3-030-02239-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation